LifeSci Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $49
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $45
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Compass Therapeutics (CMPX)
Piper Sandler Maintains Scholar Rock(SRRK.US) With Buy Rating
Piper Sandler Remains a Buy on Scholar Rock Holding (SRRK)
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Announces Target Price $45
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
TD Cowen Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial Remains a Buy on Scholar Rock Holding (SRRK)
Strategic Positioning and Market Potential: Scholar Rock Holding's Buy Rating Amidst SMA and Obesity Treatment Opportunities
Jefferies Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $50
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $57
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $50
TD Cowen Maintains Scholar Rock(SRRK.US) With Buy Rating
Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial Initiates Scholar Rock(SRRK.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50